Post by PharmaShots

Ionis Pharmaceuticals, Inc. licenses ex-US rights to Alexander disease therapy zilganersen to Recordati, leveraging Recordati’s rare disease commercialization expertise while Ionis retains US rights ahead of a Sep 2026 FDA decision Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #ionis #recordati #zilganersen #alexanderdisease #pdufa #usfda #licensingdeal #pharma #rareisease #neurology #regulatory https://lnkd.in/g9qpUAQe